Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: RT-QuiC.
- Who it may be relevant to
- Registry conditions: Idiopathic Anosmia, Idiopathic Hyposmia, Idiopathic Olfactory Dysfunction. Basic parameters: 55 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Test of early warning signs and RT-QuIC in patients with idiopathic olfactory dysfunction
Detailed description
Background. The number of persons living with dementia is increasing in Denmark and worldwide because the population is generally growing older. Dementia with Lewy bodies (DLB) is the second most prevalent etiology among the neurodegenerative diseases that give rise to dementia.
DLB is characterized by many prodromal symptoms years before dementia is evident. Currently, little is known about the course of symptoms in the prodromal phase, and furthermore, the diagnosis of DLB can be clinically challenging, especially in the early stages. DLB is like Parkinson's disease (PD), characterized by the accumulation of alpha-synuclein, which misfolds and aggregates within neurons in so-called Lewy Bodies; this assumably drives the neurodegeneration. A novel technique for the measurement of misfolded alpha-synuclein is Real-Time Quaking-Induced Conversion (RT-QuIC), which may be able to support the diagnostic process as well as aid in identifying patients with prodromal DLB. This would enable earlier symptomatic relief and care and potentially promote the search for disease-modifying therapies, which is currently absent.
Objectives. The overarching objective of this project is to identify early clinical warning signs and biomarkers in prodromal DLB.
Method. Study 1: Exploratory cross-sectional case-control study of patients with olfactory dysfunction versus individuals without olfactory dysfunction assessing pathological alpha-synuclein by RT-QuIC and prodromal symptoms of DLB and Parkinson's Disease.
Study 2: Longitudinal follow-up in Danish registries on diagnosing PD and dementia.
Interventions
- Diagnostic test RT-QuiC
RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
Primary outcome measures
- Real-time quaking-induced conversion (RT-QuIC) positive for alpha-synuclein (aSyn) [Time frame: 24 months]
- Diagnosis of Parkinson's disease (PD) or dementia [Time frame: 8 years]
Secondary outcome measures (10)
- Smell test [Time frame: 24 months]
- Smell test [Time frame: 24 months]
- Motor function [Time frame: 24 months]
- Dysautonomia and non-motor symptoms [Time frame: 24 months]
- Subjective motor symptoms [Time frame: 24 months]
- Cognition [Time frame: 24 months]
- Prodromal PD [Time frame: 24 months]
- REM-sleep [Time frame: Ever]
- Color vision [Time frame: Now]
- Co-morbidities and medication [Time frame: 10 years]
Eligibility criteria
Inclusion criteria with patients iOD:
- Age 55 -75 years of age
- Slowly progressing and non-fluctuating iOD
- Able to give informed consent and to cooperate as evaluated by the PI
Exclusion criteria with patients iOD:
- Diagnosed with a neurodegenerative disease or major neurological/psychiatric condition.
- Anosmia/hyposmia caused by sino-nasal disease (including chronic rhinitis and allergy), after trauma, infection, congenial, olfactory dysfunction due to surgery, or toxins/drugs affecting the olfactory function.
- Olfactory dysfunction with response to systemic or local corticosteroids if tried
- Severe nasal cavity abnormalities or infections.
- Overt signs of dementia or PD
- Current alcohol or drug abuse
- Terminal illness
- Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.
Inclusion criteria controls:
- Age 55 -75 years of age
- Able to give informed consent
- Able to cooperate as evaluated by the PI
Exclusion criteria controls:
- Olfactory dysfunction on clinical test
- Overt signs of dementia or PD
- Severe nasal cavity abnormalities or infections.
- Current alcohol or drug abuse
- Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-control
Study locations
Denmark · 2 centers
- Danish Dementia Research Centre — Copenhagen
- Oskar McWilliam — Copenhagen
Identifiers
NCT: NCT05740683 · H-22053428